Objective:

To describe the use of biomarker testing and therapy options for RASwt patients with metastatic colorectal cancer (mCRC) in Argentina, Brazil, and Mexico during the 2017-2019 period.

Methods:

We conducted descriptive analysis using datasets from privately-owned research tools.

Results:

There was an increase in the use of tests performed for RAS, BRAF and MSI in all three countries. Between 2018 and 2019, RAS testing increased 15% in Argentina, 29% in Brazil and 3% in Mexico. MSI testing increased 18% in Argentina and 19% in Brazil but remained stable in Mexico at 12%. BRAF testing increased 45% in Brazil, in Argentina 46% and 29% in Mexico. Main first-line available options for m CRC were: Chemotherapy (CT), CT+ (EGFR inhibitor/anti-VEGF).

Conclusions:

Given the paucity of publicly available information on access to mCRC treatments in Latin America, findings from this private data-based study may be useful for decision-making processes among healthcare institutions.

        · abstract in Spanish     · text in English     · English ( pdf )